|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Xcyte Therapies, Inc. Announces Third Quarter 2005 Financial Results
11/14/2005 1:00:58 PM
SEATTLE--(BUSINESS WIRE)--Nov. 14, 2005--Xcyte Therapies, Inc. (Xcyte, the "Company") (Nasdaq:XCYT) (Nasdaq:XCYTP) reported today a net loss of $12.6 million, or $0.64 per basic and diluted share, for the three months ended September 30, 2005, compared with a net loss of $6.8 million, or $0.46 per basic and diluted share, for the three months ended September 30, 2004. Revenue for the third quarter of 2005 was approximately $11,000, compared with approximately $13,000 for the year earlier quarter. Total operating expenses for the three months ended September 30, 2005, were $12.7 million, compared with $6.9 million for the three months ended September 30, 2004. The increase in total operating expenses was primarily the result of a provision for asset impairment, other restructuring charges and termination benefits, partially offset by reduced research and development expenses.
|
|
|
|
|
|
|
|
|
|
|